재조합 단백질 치료제 CDMO 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global recombinant protein therapeutics CDMO market size is expected to reach USD 103.65 Billion in 2034 from USD 31.35 Billion in 2025, growing at a CAGR of 14.21% during 2026-2034.The Global Recombinant Protein Therapeutics CDMO Market is experiencing strong growth driven by increasing demand for biologics and biosimilars. Pharmaceutical companies are outsourcing manufacturing to contract development and manufacturing organizations (CDMOs) to reduce costs and accelerate time-to-market. Rising prevalence of chronic diseases has significantly increased demand for protein-based therapeutics.

Major growth drivers include advancements in bioprocessing technologies, expanding biotechnology sector, and increasing regulatory approvals for biologic drugs. The growing focus on monoclonal antibodies and targeted therapies has strengthened market demand. Additionally, CDMOs offer scalable production capabilities, attracting both emerging biotech firms and established pharmaceutical companies.

Looking forward, the market is expected to benefit from innovations in cell line development and continuous manufacturing processes. Expansion of biologics pipelines and increasing investments in biopharmaceutical research will further drive growth. Emerging markets are likely to play a crucial role in expanding manufacturing capacities, ensuring sustained long-term expansion.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Type

• Growth Hormones
• Interferons
• Vaccines
• Immunostimulating Agents
• Others

By Source

• Mammalian Systems
• Microbial Systems
• Others

By Indication

• Oncology
• Infectious Diseases
• Immunological Disorders
• Metabolic Disorders
• Haematological Disorders
• Others

By Service Type

• Contract Manufacturing
• Contract Development

By End Use

• Pharmaceutical Companies
• Biotech Companies
• Others

COMPANIES PROFILED

• Lonza, Samsung Biologics, WuXi Biologics, Thermo Fisher Scientific, Catalent, Fujifilm Diosynth Biotechnologies, Boehringer Ingelheim, AGC Biologics, Rentschler Biopharma, KBI Biopharma, Just-Evotec Biologics, Emergent BioSolutions, AbbVie, Siegfried, Piramal Pharma Solutions, Curia, Cytovance Biologics, Avid Bioservices, BioVectra, Bora Pharmaceuticals

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Growth Hormones Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Interferons Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Immunostimulating Agents Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET: BY SOURCE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Source
• 5.2. Mammalian Systems Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Microbial Systems Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET: BY INDICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Indication
• 6.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Immunological Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Metabolic Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Haematological Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET: BY SERVICE TYPE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Service Type
• 7.2. Contract Manufacturing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Contract Development Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET: BY END USE 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast End Use
• 8.2. Pharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Biotech Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET: BY REGION 2022-2034 (USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Type
  • 9.2.2 By Source
  • 9.2.3 By Indication
  • 9.2.4 By Service Type
  • 9.2.5 By End Use
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Type
  • 9.3.2 By Source
  • 9.3.3 By Indication
  • 9.3.4 By Service Type
  • 9.3.5 By End Use
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Spain
  • 9.3.11 Russia
  • 9.3.12 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Type
  • 9.4.2 By Source
  • 9.4.3 By Indication
  • 9.4.4 By Service Type
  • 9.4.5 By End Use
  • 9.4.6 China
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 India
  • 9.4.10 Australia
  • 9.4.11 South East Asia
  • 9.4.12 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Type
  • 9.5.2 By Source
  • 9.5.3 By Indication
  • 9.5.4 By Service Type
  • 9.5.5 By End Use
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Type
  • 9.6.2 By Source
  • 9.6.3 By Indication
  • 9.6.4 By Service Type
  • 9.6.5 By End Use
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 Lonza
  • 11.2.2 Samsung Biologics
  • 11.2.3 WuXi Biologics
  • 11.2.4 Thermo Fisher Scientific
  • 11.2.5 Catalent
  • 11.2.6 Fujifilm Diosynth Biotechnologies
  • 11.2.7 Boehringer Ingelheim
  • 11.2.8 AGC Biologics
  • 11.2.9 Rentschler Biopharma
  • 11.2.10 KBI Biopharma
  • 11.2.11 Just-Evotec Biologics
  • 11.2.12 Emergent BioSolutions
  • 11.2.13 AbbVie
  • 11.2.14 Siegfried
  • 11.2.15 Piramal Pharma Solutions
  • 11.2.16 Curia
  • 11.2.17 Cytovance Biologics
  • 11.2.18 Avid Bioservices
  • 11.2.19 BioVectra
  • 11.2.20 Bora Pharmaceuticals